| Assessment Status |
Rapid Review Complete |
| HTA ID |
20032 |
| Drug |
Ibrutinib |
| Brand |
Imbruvica® |
| Indication |
As a single agent or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). |
| Rapid review commissioned |
06/07/2020 |
| Rapid review completed |
04/08/2020 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Ibrutinib as a single agent or in combination with obinutuzumab for adult patients with previously untreated CLL compared with the current standard of care. |
